Suvorexant for insomnia in older adults: a perspective review

Article Page

Abstract

The aim of this review was to identify published randomized control trials (RCTs) that evaluated the efficacy and tolerability of suvorexant for the treatment of insomnia among older adults (≥65 years). A literature search was conducted of PubMed, MEDLINE, EMBASE, PsycINFO and Cochrane collaboration databases for RCTs in any language evaluating suvorexant for the treatment of insomnia in older adults. Additionally, references of full-text articles that were included in this review were searched for further studies. Data from three RCTs of suvorexant were included in this review. All the three studies fulfilled the criteria for being of good quality based on the items listed by the Center for Evidence Based Medicine (CEBM) for the assessment of RCTs. None of the three studies were conducted exclusively among older adults. However, they also included older individuals diagnosed with primary insomnia. These studies included a total of 1298 participants aged ≥65 years in age. Trial durations ranged from 3 months to 1 year. Available data from these studies indicate that suvorexant improves multiple subjective and polysomnographic sleep parameters for sleep onset and maintenance among older individuals with a diagnosis of primary insomnia and is generally well tolerated. Current evidence, although limited, indicates that suvorexant benefits older adults with primary insomnia and is generally well tolerated.

Keywords: aged, elderly, geriatrics, insomnia, orexin receptor antagonists, sleep, sleep initiation and maintenance disorders, suvorexant.

Citation: Tampi RR, Manikkara G, Balachandran S, Taparia P, Hrisko S, Srinivasan S, Tampi DJ. Suvorexant for insomnia in older adults: a perspective review. Drugs in Context 2018; 7: 212517. DOI: 10.7573/dic.212517

Contributions: All authors contributed equally to the development and writing of this manuscript.

Disclosure and potential conflicts of interest: The authors have no conflicting interests to declare. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at: http://www.drugsincontext.com/wp-content/uploads/2018/01/dic.212517-COI.pdf

Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article.

Copyright: Copyright © 2018 Tampi RR, Manikkara G, Balachandran S, Taparia P, Hrisko S, Srinivasan S, Tampi DJ. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Tampi RR, Manikkara G, Balachandran S, Taparia P, Hrisko S, Srinivasan S, Tampi DJ. https://doi.org/10.7573/dic.212517. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: http://www.drugsincontext.com/suvorexant-insomnia-older-adults-perspective-review

Correspondence: Rajesh R Tampi, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Department of Psychiatry, MetroHealth, 2500 MetroHealth Drive, Cleveland, OH, 44109, USA. rajesh.tampi@gmail.com

Provenance: invited; externally peer reviewed.

Submitted: 20 November 2017; Peer review comments to author: 15 December 2017; Revised manuscript received: 17 January 2018; Accepted: 19 January 2018; Publication date: 7 February 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF